Drug Data Classification Mechanism of Action Indication Contraindications Adverse Reaction Nursing Responsibilities

Generic Name Pharmacologic Cofactor of many enzyme systems General Concentrations CNS: Weakness, Before
Magnesium Class involved in neurochemical Indications - Allergy to magnesium drowsiness, dizziness, - Assess for contraindicated
Sulfate Mineral, transmission and muscular - Constipation products fainting, sweating conditions.
Electrolyte excitability; prevents or controls - Torsades de - Abdominal pain Respiratory: Decreased - Monitor knee-jerk reflex before
Trade Name seizures by locking the pointes - Nausea respiratory rate repeated parenteral administration.
Martham Therapeutic neuromuscular transmission; - Muscle stimulating - Vomiting CV: Palpitations - Give as laxative as temporary
Class attracts and retains the water in effects of barium - Acute surgical abdomen GI: Excessive bowel measure.
Minimum Dose Antiepileptic, the intestinal lumen and distends poisoning - Fecal impaction activity, perianal irritation - Reserve IV use in eclampsia for
1-2 g qH by IV Laxative; Mineral, the bowel to promote mass - Reduction of - Intestinal and biliary tract Metabolic: Magnesium life-threatening situations.
infusion electrolyte movement and relieve cerebral oedema. obstruction intoxication, - Observe the 15 rights in drug
replacement constipation. - - Hepatitis hypocalcemia with tetany administration.
Maximum Hypomagnesaemia - Myocardial damage
Dose Pregnancy Risk Pharmacokinetics - Seizures - Heart blocks During
4-6 g qH by IV Factor associated with - 2 hr preceding delivery - Give IM route by deep IM injection.
infusion A A: Following administration, 30- epilepsy, Precaution - Monitor serum magnesium levels.
B (Laxative) 50% of the dose is absorbed from glomerulonephritis - Renal insufficiency - Do not give oral MgSO4 with
Contents the small intestine. or hypothyroidism. abdominal pain, nausea, or
Magnesium D: Crosses the placenta and small - Toxemias of Drug interaction vomiting.
sulfate amounts enter the breast milk. pregnancy Drug to drug - Do not administer if knee-jerk
M: Unknown - Boils and - Potentiation of reflexes are suppressed
Availability E: Via urine and feces. carbuncles neuromuscular - Monitor bowel function.
and color blockade produced by
- Granules- 40 mEq/5 Rout Onset Peak Duratio After
g e n nondepolarizing
- Injection- 0.325, neuromuscular - Arrange to discontinue
Oral 1-2 hr unknow 3-4 hr
0.65, 1, 4 mEq/mL n relaxants administration as soon as levels are
IM 60 min unknow 3-4 hr within normal limits and desired
Routes of n
Drug to food clinical response is obtained.
IV Immedia unknow 30 min
administration - none reported - Discontinue if diarrhea or
te n
Oral cramping occurs.
Intramuscular - Arrange for dietary measures,
Drug Half Life
Intravenous exercise and environmental control
Unknown
to return to normal bowel activity.
- Report sweating, flushing, muscle
tremors or twitching, inability to
move extremities.
- Maintain urine output at a level of
100 mL every 4 hr during parenteral
administration.
Source: Source: Source: Source: Source: Source: Source:
Karch, Amy: 2009 http://mims.com.ph/, http://mims.com.ph/, Karch, Amy: 2009 http://mims.com.ph/ Karch, Amy: 2009 Lippincott’s Karch, Amy: 2009 Lippincott’s Karch, Amy: 2009 Lippincott’s Nursing Drug
Lippincott’s Nursing Karch, Amy: 2009 Lippincott’s Nursing Drug Guide, pp. 724-725 Nursing Drug Guide, pp. 724- Nursing Drug Guide, p. 725 Guide, pp. 725-726
Drug Guide, p. 724 Lippincott’s Nursing 725
Drug Guide, pp. 724